Breaking News

Takeda, Arbor Enter Licensing Deal

September 13, 2013

Arbor to develop and market blood pressure products for U.S. market

Takeda Pharmaceutical Co. Ltd. and Arbor Pharmaceuticals Ireland Ltd. have entered into a license, development and commercialization agreement providing Arbor with exclusive rights to market EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. Takeda will receive an upfront payment along with future milestone and royalty payments based on sales.
 
"This is an opportunity to capture the value that we've created in developing and launching the EDARBI family of products while positioning us to optimize our commercial resources to support our recent and anticipated launches of new products," said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. "We are pleased to entrust the EDARBI family in the United States to Arbor who will continue to ensure EDARBI products are available as a treatment option to patients with hypertension. Takeda maintains its global commitment to find new therapies and expand upon the cardiovascular metabolic franchise. The EDARBI family of products remains a priority for a variety of Takeda's markets globally."
 
"We are excited about our acquisition of U.S. rights to EDARBI and EDARBYCLOR and look forward to representing these important brands to patients and healthcare providers," said Ed Schutter, president and chief executive officer of Arbor. "As a specialty pharmaceutical company already focused in the cardiovascular area, we are well-positioned to ensure the EDARBI products are available to all appropriate patients who may need them."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.